Further data to question the use of alloBMT in AML CR1 in addition to intensive chemotherapy. The MRC experience in 715 patients under 44 years with donors available

AK Burnett, Keith Wheatley, R Stevens, AH Goldstone, I Hann, AG Prentice, Donald Milligan, B Gibson, D Webb

Research output: Contribution to conference (unpublished)Paper

Original languageEnglish
Pages74a Abs 269
Publication statusPublished - 1 Jan 2002

Cite this